<unk>  is an monoclonal antibody that is FDA approved for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V400 mutation positive, a BRAF inhibitor.   Common adverse reactions include pruritus, rash , hyperkalemia , hyponatremia
alkaline phosphatase raised , ALT/SGPT level raised , AST/SGOT level raised , Serum bilirubin raised ,Serum creatinine raised ,Cough , Upper respiratory infection.
Nivolumab
Pembrolizumab
Risankizumab
Adecatumumab
Daratumumab
Idarucizumab
Ofatumumab
Crizotinib